[Congressional Record (Bound Edition), Volume 150 (2004), Part 16]
[House]
[Pages 22751-22752]
[From the U.S. Government Publishing Office, www.gpo.gov]




                  ANABOLIC STEROID CONTROL ACT OF 2004

  Mr. CANNON. Mr. Speaker, I ask unanimous consent to take from the 
Speaker's table the Senate bill (S. 2195) to amend the Controlled 
Substances Act to clarify the definition of anabolic steroids and to 
provide for research and education activities relating to steroids and 
steroid precursors, and ask for its immediate consideration in the 
House.
  The Clerk read the title of the Senate bill.
  The SPEAKER pro tempore. Is there objection to the request of the 
gentleman from Utah?
  There was no objection.
  The Clerk read the Senate bill, as follows:

                                S. 2195

       Be it enacted by the Senate and House of Representatives of 
     the United States of America in Congress assembled,

     SECTION 1. SHORT TITLE.

       This Act may be cited as the ``Anabolic Steroid Control Act 
     of 2004''.

     SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT.

       (a) Definitions.--Section 102 of the Controlled Substances 
     Act (21 U.S.C. 802) is amended--
       (1) in paragraph (41)--
       (A) by realigning the margin so as to align with paragraph 
     (40); and
       (B) by striking subparagraph (A) and inserting the 
     following:
       ``(A) The term `anabolic steroid' means any drug or 
     hormonal substance, chemically and pharmacologically related 
     to testosterone (other than estrogens, progestins, 
     corticosteroids, and dehydroepiandrosterone), and includes--
       ``(i) androstanediol--
       ``(I) 3b,17b-dihydroxy-5a-androstane; and
       ``(II) 3a,17b-dihydroxy-5a-androstane;
       ``(ii) androstanedione (5a-androstan-3,17-dione);
       ``(iii) androstenediol--
       ``(I) 1-androstenediol (3b,17b-dihydroxy-5a-androst-1-ene);
       ``(II) 1-androstenediol (3a,17b-dihydroxy-5a-androst-1-
     ene);
       ``(III) 4-androstenediol (3b,17b-dihydroxy-androst-4-ene); 
     and
       ``(IV) 5-androstenediol (3b,17b-dihydroxy-androst-5-ene);
       ``(iv) androstenedione--
       ``(I) 1-androstenedione ([5a]-androst-1-en-3,17-dione);
       ``(II) 4-androstenedione (androst-4-en-3,17-dione); and
       ``(III) 5-androstenedione (androst-5-en-3,17-dione);
       ``(v) bolasterone (7a,17a-dimethyl-17b-hydroxyandrost-4-en-
     3-one);
       ``(vi) boldenone (17b-hydroxyandrost-1,4,-diene-3-one);
       ``(vii) calusterone (7b,17a-dimethyl-17b-hydroxyandrost-4-
     en-3-one);
       ``(viii) clostebol (4-chloro-17b-hydroxyandrost-4-en-3-
     one);
       ``(ix) dehydrochloromethyltestosterone (4-chloro-17b-
     hydroxy-17a-methyl-androst-1,4-dien-3-one);
       ``(x) 1-dihydrotestosterone (a.k.a. `1-
     testosterone') (17b-hydroxy-5a-androst-1-en-3-one);
       ``(xi) 4-dihydrotestosterone (17b-hydroxy-androstan-3-one);
       ``(xii) drostanolone (17b-hydroxy-2a-methyl-5a-androstan-3-
     one);
       ``(xiii) ethylestrenol (17a-ethyl-17b-hydroxyestr-4-ene);
       ``(xiv) fluoxymesterone (9-fluoro-17a-methyl-11b,17b-
     dihydroxyandrost-4-en-3-one);
       ``(xv) formebolone (2-formyl-17a-methyl-11a,17b-
     dihydroxyandrost-1,4-dien-3-one);
       ``(xvi) furazabol (17a-methyl-17b-hydroxyandrostano[2,3-c]-
     furazan);
       ``(xvii) 13b-ethyl-17a-hydroxygon-4-en-3-one;
       ``(xviii) 4-hydroxytestosterone (4,17b-dihydroxy-androst-4-
     en-3-one);
       ``(xix) 4-hydroxy-19-nortestosterone (4,17b-dihydroxy-estr-
     4-en-3-one);
       ``(xx) mestanolone (17a-methyl-17b-hydroxy-5a-androstan-3-
     one);
       ``(xxi) mesterolone (1a-methyl-17b-hydroxy-[5a]-androstan-
     3-one);
       ``(xxii) methandienone (17a-methyl-17b-hydroxyandrost-1,4-
     dien-3-one);
       ``(xxiii) methandriol (17a-methyl-3b,17b-dihydroxyandrost-
     5-ene);
       ``(xxiv) methenolone (1-methyl-17b-hydroxy-5a-androst-1-en-
     3-one);
       ``(xxv) 17a-methyl-3b, 17b-dihydroxy-5a-androstane;
       ``(xxvi) 17a-methyl-3a,17b-dihydroxy-5a-androstane;
       ``(xxvii) 17a-methyl-3b,17b-dihydroxy-
     androst-4-ene.
       ``(xxviii) 17a-methyl-4-hydroxynandrolone (17a-methyl-4-
     hydroxy-17b-hydroxyestr-4-en-3-one);
       ``(xxix) methyldienolone (17a-methyl-17b-hydroxyestra-
     4,9(10)-dien-3-one);
       ``(xxx) methyltrienolone (17a-methyl-17b-hydroxyestra-4,9-
     11-trien-3-one);
       ``(xxxi) methyltestosterone (17a-methyl-17b-hydroxyandrost-
     4-en-3-one);
       ``(xxxii) mibolerone (7a,17a-dimethyl-17b-hydroxyestr-4-en-
     3-one);
       ``(xxxiii) 17a-methyl-1-dihydrotestosterone (17b-
     hydroxy-17a-methyl-5a-androst-1-en-3-one) (a.k.a. `17-a-
     methyl-1-testosterone');
       ``(xxxiv) nandrolone (17b-hydroxyestr-4-en-3-one);
       ``(xxxv) norandrostenediol--
       ``(I) 19-nor-4-androstenediol (3b, 17b-dihydroxyestr-4-
     ene);
       ``(II) 19-nor-4-androstenediol (3a, 17b-dihydroxyestr-4-
     ene);
       ``(III) 19-nor-5-androstenediol (3b, 17b-dihydroxyestr-5-
     ene); and
       ``(IV) 19-nor-5-androstenediol (3a, 17b-dihydroxyestr-5-
     ene);
       ``(xxxvi) norandrostenedione--
       ``(I) 19-nor-4-androstenedione (estr-4-en-3,17-dione); and
       ``(II) 19-nor-5-androstenedione (estr-5-en-3,17-dione;
       ``(xxxvii) norbolethone (13b,17a-diethyl-17b-hydroxygon-4-
     en-3-one);
       ``(xxxviii) norclostebol (4-chloro-17b-hydroxyestr-4-en-3-
     one);
       ``(xxxix) norethandrolone (17a-ethyl-17b-hydroxyestr-4-en-
     3-one);
       ``(xl) normethandrolone (17a-methyl-17b-hydroxyestr-4-en-3-
     one);
       ``(xli) oxandrolone (17a-methyl-17b-hydroxy-2-oxa-[5a]-
     androstan-3-one);
       ``(xlii) oxymesterone (17a-methyl-4,17b-dihydroxyandrost-4-
     en-3-one);
       ``(xliii) oxymetholone (17a-methyl-2-hydroxymethylene-17b-
     hydroxy-[5a]-androstan-3-one);
       ``(xliv) stanozolol (17a-methyl-17a-hydroxy-[5a]-androst-2-
     eno[3,2-c]-pyrazole);
       ``(xlv) stenbolone (17b-hydroxy-2-methyl-[5a]-androst-1-en-
     3-one);
       ``(xlvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-
     1,4-dien-17-oic acid lactone);
       ``(xlvii) testosterone (17b-hydroxyandrost-4-en-3-one);
       ``(xlviii) tetrahydrogestrinone (13b,17a-diethyl-17b-
     hydroxygon-4,9,11-trien-3-one);
       ``(xlix) trenbolone (17b-hydroxyestr-4,9,11-trien-3-one); 
     and
       ``(xlx) any salt, ester, or ether of a drug or substance 
     described in this paragraph.
     The substances excluded under this subparagraph may at any 
     time be scheduled by the Attorney General in accordance with 
     the authority and requirements of subsections (a) through (c) 
     of section 201.''; and
       (2) in paragraph (44), by inserting ``anabolic steroids,'' 
     after ``marihuana,''.
       (b) Authority and Criteria for Classification.--Section 
     201(g) of the Controlled Substances Act (21 U.S.C. 811(g)) is 
     amended--
       (1) in paragraph (1), by striking ``substance from a 
     schedule if such substance'' and inserting ``drug which 
     contains a controlled substance from the application of 
     titles II and III of the Comprehensive Drug Abuse Prevention 
     and Control Act (21 U.S.C. 802 et seq.) if such drug''; and
       (2) in paragraph (3), by adding at the end the following:
       ``(C) Upon the recommendation of the Secretary of Health 
     and Human Services, a compound, mixture, or preparation which 
     contains any anabolic steroid, which is intended for 
     administration to a human being or an animal, and which, 
     because of its concentration, preparation, formulation or 
     delivery system, does not present any significant potential 
     for abuse.''.
       (c) Anabolic Steroids Control Act.--Section 1903 of the 
     Anabolic Steroids Control Act of 1990 (Public Law 101-647) is 
     amended--
       (1) by striking subsection (a); and
       (2) by redesignating subsections (b) and (c) as subsections 
     (a) and (b), respectively.
       (d) Effective Date.--The amendments made by this section 
     shall take effect 90 days after the date of enactment of this 
     Act.

     SEC. 3. SENTENCING COMMISSION GUIDELINES.

       The United States Sentencing Commission shall--
       (1) review the Federal sentencing guidelines with respect 
     to offenses involving anabolic steroids;
       (2) consider amending the Federal sentencing guidelines to 
     provide for increased penalties with respect to offenses 
     involving anabolic steroids in a manner that reflects the 
     seriousness of such offenses and the need

[[Page 22752]]

     to deter anabolic steroid trafficking and use; and
       (3) take such other action that the Commission considers 
     necessary to carry out this section.

     SEC. 4. PREVENTION AND EDUCATION PROGRAMS.

       (a) In General.--The Secretary of Health and Human Services 
     (referred to in this Act as the ``Secretary'') shall award 
     grants to public and nonprofit private entities to enable 
     such entities to carry out science-based education programs 
     in elementary and secondary schools to highlight the harmful 
     effects of anabolic steroids.
       (b) Eligibility.--
       (1) Application.--To be eligible for grants under 
     subsection (a), an entity shall prepare and submit to the 
     Secretary an application at such time, in such manner, and 
     containing such information as the Secretary may require.
       (2) Preference.--In awarding grants under subsection (a), 
     the Secretary shall give preference to applicants that intend 
     to use grant funds to carry out programs based on--
       (A) the Athletes Training and Learning to Avoid Steroids 
     program;
       (B) The Athletes Targeting Healthy Exercise and Nutrition 
     Alternatives program; and
       (C) other programs determined to be effective by the 
     National Institute on Drug Abuse.
       (c) Use of Funds.--Amounts received under a grant under 
     subsection (a) shall be used for education programs that will 
     directly communicate with teachers, principals, coaches, as 
     well as elementary and secondary school children concerning 
     the harmful effects of anabolic steroids.
       (d) Authorization of Appropriations.--There is authorized 
     to be appropriated to carry out this section, $15,000,000 for 
     each of fiscal years 2005 through 2010.

     SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH.

       (a) In General.--The Secretary of Health and Human Services 
     shall ensure that the National Survey on Drug Use and Health 
     includes questions concerning the use of anabolic steroids.
       (b) Authorization of Appropriations.--There is authorized 
     to be appropriated to carry out this section, $1,000,000 for 
     each of fiscal years 2005 through 2010.

  The Senate bill was ordered to be read a third time, was read the 
third time, and passed, and a motion to reconsider was laid on the 
table.

                          ____________________